ArticleClinical rheumatology2026
Therapeutic effects of ginkgetin on rheumatoid arthritis: evidence from network pharmacology and experimental validation.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial hyperplasia, persistent inflammation, and progressive joint destruction. Ginkgetin (GK), a biflavonoid derived from Ginkgo biloba, exhibits strong anti-inflammatory and antioxidant properties. However, its therapeutic potential and underlying molecular mechanisms in RA remain insufficiently understood.
methodsAn integrative strategy combining network pharmacology, transcriptomic profiling, molecular docking, and in vitro experiments was applied to elucidate the mechanisms of GK against RA. Differentially expressed genes (DEGs) were identified from four GEO datasets of RA synovial tissues, and overlapping targets between GK and RA were screened. Gene Ontology (GO), KEGG pathway enrichment, and protein-protein interaction (PPI) analyses were conducted to identify key pathways and hub genes. Molecular docking and single-cell transcriptomic analyses were performed to predict binding interactions and cellular localization. Finally, MH7A synovial fibroblasts were used to validate GK's effects on inflammation, proliferation, migration, and apoptosis.
resultsThirty-two potential therapeutic targets of GK in RA were identified, among which six hub genes (CXCR4, HIF1A, STAT1, VEGFA, CDK1, and CCNB1) were highlighted. Enrichment analyses indicated that these targets were primarily involved in the HIF-1, VEGF, and cell cycle signaling pathways. Molecular docking demonstrated strong binding affinities between GK and key proteins. In vitro, GK inhibited LPS-induced proliferation and migration of MH7A cells, reduced IL-6 and IL-1β expression, and promoted apoptosis. qRT-PCR analysis confirmed that GK downregulated all six hub genes, indicating its multi-target regulatory activity on hypoxia, angiogenesis, and inflammatory signaling.
conclusionGK exerts anti-inflammatory, anti-proliferative, and pro-apoptotic effects in RA synovial fibroblasts by modulating multiple signaling pathways, particularly the HIF-1α/VEGFA, STAT1, and CXCR4 axes. These findings provide mechanistic insight into GK's pharmacological actions and support its potential as a novel multi-target therapeutic candidate for RA. Key Points •Network pharmacology identified six hub genes (CXCR4, HIF1A, STAT1, VEGFA, CDK1, CCNB1) linking Ginkgetin (GK) to rheumatoid arthritis pathology. •Molecular docking confirmed strong binding affinities of GK with key targets, supporting its multitarget pharmacological potential. •GK inhibits proliferation and migration, suppresses inflammatory cytokines, and promotes apoptosis in LPS-stimulated MH7A synovial fibroblasts. •These findings provide mechanistic evidence supporting GK as a promising multi-target candidate for rheumatoid arthritis therapy.
Indexed as
Identifiers
41963573What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.